Federal Agency for Medicines and Health Products, Belgium (FAMHP) has completed the European Union Good Manufacturing Practice (EU GMP) inspection at Bharat Parenterals’ subsidiary -- Innoxel Lifesciences’ manufacturing facility.
The inspection was carried out at the Innoxel Lifesciences’ manufacturing facility from November 24, 2025 to November 28, 2025. The audit was completed with zero critical and zero major observations, reflecting the company’s strong quality systems, robust manufacturing infrastructure, and strict adherence to global regulatory standards.
This milestone further strengthens the company’s regulatory credentials following its earlier successful USFDA inspection outcomes and reinforces its position as a trusted partner in regulated international markets.
Bharat Parenterals is engaged in to the business of the Pharmaceuticals & Drugs.
